Government-Owned Inventions; Availability for Licensing, 2287-2288 [E7-626]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 11 / Thursday, January 18, 2007 / Notices
For Further Information Contact: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Charles Land,
Project Officer, National Cancer
Institute, EPS , 6120 Executive
Boulevard MSC 7238, Bethesda,
Maryland 20852, or call non-toll free
number 301–594–7165 or FAX your
request, including your address to 301–
402–0207.
Comments Due Date
Comments regarding this information
collection are best assured of having
their full effect if received within 60
days of this publication.
Dated: January 8, 2007.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. E7–625 Filed 1–17–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
pwalker on PROD1PC71 with NOTICES
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Novel Benztropine Analogs for
Treatment of Cocaine Abuse and Other
Mental Disorders
Description of Technology: Dopamine
is a neurotransmitter that exerts
important effects on locomotor activity,
VerDate Aug<31>2005
17:52 Jan 17, 2007
Jkt 211001
motivation and reward, and cognition.
The dopamine transporter (DAT) is
expressed on the plasma membrane of
dopamine synthesizing neurons, and is
responsible for clearing dopamine
released into the extra-cellular space,
thereby regulating neurotransmission.
The dopamine transporter plays a
significant role in neurotoxicity and
human diseases, such as Parkinson’s
disease, drug abuse (especially cocaine
addiction), Attention Deficit Disorder/
Attention Deficit Hyperactivity Disorder
(ADD/ADHD), and a number of other
CNS disorders. Therefore, the dopamine
transporter is a strong target for research
and the discovery of potential
therapeutics for the treatment of these
indications.
This invention discloses novel
benztropine analogs and methods of
using these analogs for treatment of
mental and conduct disorders such as
cocaine abuse, narcolepsy, ADHD,
obesity and nicotine abuse. The
disclosed analogs are highly selective
and potent inhibitors of DAT, but
without an apparent cocaine-like
behavioral profile. In addition to their
use as a treatment for cocaine abuse,
these compounds have also shown
efficacy in animal models of ADHD and
nicotine abuse, and have also been
shown to reduce food intake in animals.
They may also be useful medications for
other indications where dopaminerelated behavior is compromised, such
as alcohol addiction, tobacco addiction,
and Parkinson’s disease.
Applications: Drug leads for treatment
of cocaine abuse, ADHD, nicotine abuse,
obesity, and other dopamine-related
disorders; Imaging probes for dopamine
transporter binding sites.
Development Status: Pre-clinical data
are available.
Inventors: Amy H. Newman, Mu-fa
Zou, and Jonathan L. Katz (NIDA).
Patent Status: U.S. Provisional
Application No. 60/710,956 filed 24
Aug 2005 (HHS Reference No. E–234–
2005/0–US–01); PCT Application No.
PCT/US2006/33103 filed 24 Aug 2006
(HHS Reference No. E–234–2005/1–
PCT–01 and HHS Reference No. E–129–
2006/0).
Licensing Status: Available for
exclusive or nonexclusive licensing.
Licensing Contact: Tara Kirby, Ph.D.;
301/435–4426; tarak@mail.nih.gov.
Collaborative Research Opportunity:
The Medicinal Chemistry and
Psychobiology Sections, National
Institute on Drug Abuse-Intramural
Research Program, National Institutes of
Health, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
2287
commercialize medications to treat
cocaine abuse and addiction. Please
contact John D. Hewes, Ph.D. at 301/
435–3121 or hewesj@mail.nih.gov for
more information.
Protein Arginine N-methyltransferase 2
(PRMT–2), a Modulator of NFKB, E2F1,
and STAT3 Activity
Description of Technology: Proteinarginine methyltransferases (PRMTs)
contain methyltransferase domains that
modify chromatin and regulate cellular
transcription through the posttranslational methylation of arginine
residues on the guanidine group of
target proteins. Members of this family
have roles in RNA processing,
transcriptional regulation, signal
transduction, and DNA repair. Until
recently, the functional significance of
one member of this family, PRMT–2,
was unknown.
Researchers at NHLBI, led by Dr.
Elizabeth Nabel, have elucidated the
role of PRMT–2. They have found that
PRMT–2 modulates the activity of
NFKB, E2F1, and STAT3. PRMT–2
inhibits NFKB dependent transcription,
and therefore PRMT–2 has a role in
modulating inflammation and the
immune response. Also, PRMT–2
proteins can repress E2F1
transcriptional activity and cause cell
cycle arrest, and thus may be used to
treat or prevent cancer. PRMT–2 also
methylates STAT3, and inhibition or
loss of PRMT–2 function causes
mammals to lose weight, eat less and
become more sensitive to insulin.
The invention describes methods of
modulating PRMT–2 activity or
expression in cells. These methods can
be used to inhibit the function of NF?B,
E2F1 and STAT3 for treatment of a
number of disorders, including
inflammation, cancer, and diabetes.
Applications: Target for treatment and
study of a number of disorders,
including:
Diabetes, obesity and metabolic
syndrome diseases; Inflammation and
immune response-related disorders;
Cancer.
Inventors: Elizabeth Nabel (NHLBI),
Hiroaki Iwasaki (NHLBI), Takanobu
Yoshimoto (NHLBI), and Gary Nabel
(NIAID).
Patent Status: U.S. Provisional
Application No. 60/466,751 filed 30
April 2003 (HHS Reference No. E–190–
2003/0–US–01); PCT Application No.
PCT2004/013375 filed 30 April 2004,
which published as WO 2004/098634
on 18 Nov 2004 (HHS Reference No. E–
190–2003/0–PCT–02); U.S. Application
No. 11/263,657 filed 31 Oct 2005, which
published as WO 2006/0239990 on 26
E:\FR\FM\18JAN1.SGM
18JAN1
2288
Federal Register / Vol. 72, No. 11 / Thursday, January 18, 2007 / Notices
Oct 2006 (HHS Reference No. E–190–
2003/0–US–04).
Licensing Status: Available for
exclusive or nonexclusive licensing.
Licensing Contact: Tara Kirby, Ph.D.;
301/435–4426; tarak@mail.nih.gov.
Dated: January 9, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–626 Filed 1–17–07; 8:45 am]
pwalker on PROD1PC71 with NOTICES
VerDate Aug<31>2005
17:52 Jan 17, 2007
Jkt 211001
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meeting
BILLING CODE 4140–01–P
Methods for Assaying Hair Follicle
Growth and Development
Description of Technology: Methods
of culturing functionally-intact hair
follicles in a collagen matrix are useful
for screening baldness treatments and
the quantification and study of the
effects of agents on hair follicle growth.
This technology describes techniques
for measuring cell proliferation or for
measuring secretion of collagenolytic
factors, incorporating a threedimensional hair follicle culture system.
Collagenolytic activity is essential for
downgrowth of hair follicles during
anagen. One described method
measures the effects of a growth factor
or pharmaceutical compound on cell
proliferation, utilizing the incorporation
of tritiated thymidine into DNA of
cultured hair follicles. Also described is
a method to measure the effect of
growth factors on the release of
collagenolytic factors, utilizing tritiated
collagen or a fluorescent marker.
Applications: Assays for screening
drugs or growth factors that may
stimulate hair growth; Assays measuring
the DNA synthesis and collagenasesecreting activity of hair follicles.
Market: An estimated 40 million men
and 20 million women suffer from hair
loss; The market size for hair restoration
procedures in the United States is
approximately $800 million.
Inventor: Stuart H. Yuspa (NCI).
Publications:
1. G Rogers, N Martinet, P Steinert, P
Wynn, D Roop, A Kilkenny, D Morgan,
SH Yuspa. Cultivation of murine hair
follicles as organoids in a collagen
matrix. J Invest Dermatol. 1987
Oct;89(4):369–379.
2. W Weinberg, P Brown, WG StetlerStevenson, SH Yuspa, Growth factors
specifically alter hair follicle cell
proliferation and collagenolytic activity
alone or in combination. Differentiation.
1990 Dec;45(3):168–178.
Patent Status: U.S. Patent No.
5,616,471 issued 01 Apr 1997 (HHS
Reference No. E–213–1987/1–US–01).
Licensing Status: Available for
nonexclusive licensing.
Licensing Contact: Tara Kirby, Ph.D.;
301/435–4426; tarak@mail.nih.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Initial Review Group, Subcommittee
G—Education.
Date: February 6–7, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Court Hotel, 525 New
Jersey Avenue, NW., Washington, DC 20001.
Contact Person: Sonya Roberson, PhD,
Scientific Review Administrator, Resources
and Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., Room 8109,
Bethesda, MD 20892, 301–594–1182,
robersos@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: January 9, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–178 Filed 1–17–07; 8:45 am]
BILLING CODE 4140–01–M
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Heart, Lung, and Blood
Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed blow in
advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Advisory Council.
Date: February 14, 2007.
Open: 8 a.m. to 12 p.m.
Agenda: Discussion of program policies
and issues.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Closed: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Contact Person: Stephen Mockrin, PhD,
Director, Division of Extramural Research
Activities, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Room 7100, Bethesda, MD
20892, (301) 435–0260,
mockrins@nhlbi.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
E:\FR\FM\18JAN1.SGM
18JAN1
]]>Agencies
[Federal Register Volume 72, Number 11 (Thursday, January 18, 2007)]
[Notices]
[Pages 2287-2288]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-626]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Novel Benztropine Analogs for Treatment of Cocaine Abuse and Other
Mental Disorders
Description of Technology: Dopamine is a neurotransmitter that
exerts important effects on locomotor activity, motivation and reward,
and cognition. The dopamine transporter (DAT) is expressed on the
plasma membrane of dopamine synthesizing neurons, and is responsible
for clearing dopamine released into the extra-cellular space, thereby
regulating neurotransmission. The dopamine transporter plays a
significant role in neurotoxicity and human diseases, such as
Parkinson's disease, drug abuse (especially cocaine addiction),
Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder
(ADD/ADHD), and a number of other CNS disorders. Therefore, the
dopamine transporter is a strong target for research and the discovery
of potential therapeutics for the treatment of these indications.
This invention discloses novel benztropine analogs and methods of
using these analogs for treatment of mental and conduct disorders such
as cocaine abuse, narcolepsy, ADHD, obesity and nicotine abuse. The
disclosed analogs are highly selective and potent inhibitors of DAT,
but without an apparent cocaine-like behavioral profile. In addition to
their use as a treatment for cocaine abuse, these compounds have also
shown efficacy in animal models of ADHD and nicotine abuse, and have
also been shown to reduce food intake in animals. They may also be
useful medications for other indications where dopamine-related
behavior is compromised, such as alcohol addiction, tobacco addiction,
and Parkinson's disease.
Applications: Drug leads for treatment of cocaine abuse, ADHD,
nicotine abuse, obesity, and other dopamine-related disorders; Imaging
probes for dopamine transporter binding sites.
Development Status: Pre-clinical data are available.
Inventors: Amy H. Newman, Mu-fa Zou, and Jonathan L. Katz (NIDA).
Patent Status: U.S. Provisional Application No. 60/710,956 filed 24
Aug 2005 (HHS Reference No. E-234-2005/0-US-01); PCT Application No.
PCT/US2006/33103 filed 24 Aug 2006 (HHS Reference No. E-234-2005/1-PCT-
01 and HHS Reference No. E-129-2006/0).
Licensing Status: Available for exclusive or nonexclusive
licensing.
Licensing Contact: Tara Kirby, Ph.D.; 301/435-4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity: The Medicinal Chemistry and
Psychobiology Sections, National Institute on Drug Abuse-Intramural
Research Program, National Institutes of Health, is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize medications to
treat cocaine abuse and addiction. Please contact John D. Hewes, Ph.D.
at 301/435-3121 or hewesj@mail.nih.gov for more information.
Protein Arginine N-methyltransferase 2 (PRMT-2), a Modulator of
NF[Kappa]B, E2F1, and STAT3 Activity
Description of Technology: Protein-arginine methyltransferases
(PRMTs) contain methyltransferase domains that modify chromatin and
regulate cellular transcription through the post-translational
methylation of arginine residues on the guanidine group of target
proteins. Members of this family have roles in RNA processing,
transcriptional regulation, signal transduction, and DNA repair. Until
recently, the functional significance of one member of this family,
PRMT-2, was unknown.
Researchers at NHLBI, led by Dr. Elizabeth Nabel, have elucidated
the role of PRMT-2. They have found that PRMT-2 modulates the activity
of NF[Kappa]B, E2F1, and STAT3. PRMT-2 inhibits NF[Kappa]B dependent
transcription, and therefore PRMT-2 has a role in modulating
inflammation and the immune response. Also, PRMT-2 proteins can repress
E2F1 transcriptional activity and cause cell cycle arrest, and thus may
be used to treat or prevent cancer. PRMT-2 also methylates STAT3, and
inhibition or loss of PRMT-2 function causes mammals to lose weight,
eat less and become more sensitive to insulin.
The invention describes methods of modulating PRMT-2 activity or
expression in cells. These methods can be used to inhibit the function
of NF?B, E2F1 and STAT3 for treatment of a number of disorders,
including inflammation, cancer, and diabetes.
Applications: Target for treatment and study of a number of
disorders, including:
Diabetes, obesity and metabolic syndrome diseases; Inflammation and
immune response-related disorders; Cancer.
Inventors: Elizabeth Nabel (NHLBI), Hiroaki Iwasaki (NHLBI),
Takanobu Yoshimoto (NHLBI), and Gary Nabel (NIAID).
Patent Status: U.S. Provisional Application No. 60/466,751 filed 30
April 2003 (HHS Reference No. E-190-2003/0-US-01); PCT Application No.
PCT2004/013375 filed 30 April 2004, which published as WO 2004/098634
on 18 Nov 2004 (HHS Reference No. E-190-2003/0-PCT-02); U.S.
Application No. 11/263,657 filed 31 Oct 2005, which published as WO
2006/0239990 on 26
[[Page 2288]]
Oct 2006 (HHS Reference No. E-190-2003/0-US-04).
Licensing Status: Available for exclusive or nonexclusive
licensing.
Licensing Contact: Tara Kirby, Ph.D.; 301/435-4426;
tarak@mail.nih.gov.
Methods for Assaying Hair Follicle Growth and Development
Description of Technology: Methods of culturing functionally-intact
hair follicles in a collagen matrix are useful for screening baldness
treatments and the quantification and study of the effects of agents on
hair follicle growth. This technology describes techniques for
measuring cell proliferation or for measuring secretion of
collagenolytic factors, incorporating a three-dimensional hair follicle
culture system. Collagenolytic activity is essential for downgrowth of
hair follicles during anagen. One described method measures the effects
of a growth factor or pharmaceutical compound on cell proliferation,
utilizing the incorporation of tritiated thymidine into DNA of cultured
hair follicles. Also described is a method to measure the effect of
growth factors on the release of collagenolytic factors, utilizing
tritiated collagen or a fluorescent marker.
Applications: Assays for screening drugs or growth factors that may
stimulate hair growth; Assays measuring the DNA synthesis and
collagenase-secreting activity of hair follicles.
Market: An estimated 40 million men and 20 million women suffer
from hair loss; The market size for hair restoration procedures in the
United States is approximately $800 million.
Inventor: Stuart H. Yuspa (NCI).
Publications:
1. G Rogers, N Martinet, P Steinert, P Wynn, D Roop, A Kilkenny, D
Morgan, SH Yuspa. Cultivation of murine hair follicles as organoids in
a collagen matrix. J Invest Dermatol. 1987 Oct;89(4):369-379.
2. W Weinberg, P Brown, WG Stetler-Stevenson, SH Yuspa, Growth
factors specifically alter hair follicle cell proliferation and
collagenolytic activity alone or in combination. Differentiation. 1990
Dec;45(3):168-178.
Patent Status: U.S. Patent No. 5,616,471 issued 01 Apr 1997 (HHS
Reference No. E-213-1987/1-US-01).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Tara Kirby, Ph.D.; 301/435-4426;
tarak@mail.nih.gov.
Dated: January 9, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-626 Filed 1-17-07; 8:45 am]
BILLING CODE 4140-01-P
